BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT00777036
- Locations
- 🇮🇹
Local Institution - 006, Monza, Italy
🇲🇽Local Institution - 0050, Monterrey, Nuevo Leon, Mexico
🇷🇺Local Institution - 0023, Moscow, Russian Federation
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00773344
- Locations
- 🇺🇸
Premiere Oncology Of Arizona, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Phase IIB Pilot of Atazanavir + Raltegravir
- Conditions
- HIV
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 167
- Registration Number
- NCT00768989
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇫🇷Local Institution, Paris Cedex 20, France
🇺🇸Yale University School Of Medicine, New Haven, Connecticut, United States
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 155
- Registration Number
- NCT00767520
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸Compassionate Cancer Care Medical Group, Inc, Fountain Valley, California, United States
🇺🇸Compassionate Cancer Care Medical Group Inc, Riverside, California, United States
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT00767325
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2012-02-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT00764309
- Locations
- 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸Boston University School Of Medicine, Boston, Massachusetts, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT00754325
- Locations
- 🇺🇸
Kansas City Cancer Center, Llc., Overland Park, Kansas, United States
🇺🇸Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
🇺🇸Us Oncology Research, Inc., Houston, Texas, United States
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1930
- Registration Number
- NCT00744497
- Locations
- 🇺🇸
Maine Center For Cancer Medicine, Scarborough, Maine, United States
🇺🇸Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States
🇺🇸Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00743938
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Hema/Oncology Assoc. Of Nepa, Dunmore, Pennsylvania, United States
🇺🇸Cancer Center Of The Carolinas, Greenville, South Carolina, United States
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Chronic
- Interventions
- Biological: Ipilimumab
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00732186
- Locations
- 🇺🇸
The University Of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States